SMAD genes are up‐regulated in brain and blood samples of individuals with schizophrenia

Abstract

AbstractSchizophrenia is a severe psychiatric disorder, with heritability around 80%, but a not fully understood pathophysiology. Signal transduction through the mothers against decapentaplegic (SMADs) are eight different proteins involved in the regulation of inflammatory processes, cell cycle, and tissue patterning. The literature is not consistent regarding the differential expression of SMAD genes among subjects with schizophrenia. In this article, we performed a systematic meta‐analysis of the expression of SMAD genes in 423 brain samples (211 schizophrenia vs. 212 healthy controls), integrating 10 datasets from two public repositories, following the PRISMA guidelines. We found a statistically significant up‐regulation of SMAD1, SMAD4, SMAD5, and SMAD7, and a tendency for up‐regulation of SMAD3 and SMAD9 in brain samples of patients with schizophrenia. Overall, six of the eight genes showed a tendency for up‐regulation, and none of them was found to have a tendency for down‐regulation. SMAD1 and SMAD4 were up‐regulated also in blood samples of 13 individuals with schizophrenia versus eight healthy controls, suggesting the SMAD genes' potential role as biomarkers of schizophrenia. Furthermore, SMAD genes' expression levels were significantly correlated with those of Sphingosine‐1‐phosphate receptor‐1 (S1PR1), which is known to regulate inflammatory processes. Our meta‐analysis supports the involvement of SMAD genes in the pathophysiology of schizophrenia through their role in inflammatory processes, as well as demonstrates the importance of gene expression meta‐analysis for improving our understanding of psychiatric diseases.